Global Acute Repetitive Seizures Market Worth Around $4.0 Billion By 2026: Acumen Research and Consulting

Author: Acumen Research and Consulting

The global acute repetitive seizures market size is anticipated to reach USD 4.0 billion by 2026, registering at a CAGR growth of 48.6% over the forecast period. High unmet clinical demand for patients, as well as caregivers, and accessibility of progressive product pipeline are some of the main factors anticipated to push industry development. Drug therapy is operative for many of the patients suffering from cluster seizures. Though, there are an important numeral of treatment challenges and unmet medical demand such as drug induced seizures, adverse reactions, and lack of ant epileptogenic agents that can prevent growth of seizures and its comorbidities.

While trying to check medicinal services consumption, governments over the globe are trying constant endeavors to lessen doctor's facility stays and on location tolerant treatment costs through outpatient care models, for example, clinic and home healthcare. Developing economies like India and China are progressively executing these human services changes. This factor is relied upon to impel the development of acute repetitive seizures market.

Download Report Sample Pages For Better Understanding@ 

The treatment gap is a helpful measure to contrast access with quality consideration for patients experiencing seizures. The treatment gap for low-and middle-income nations, for example, India, South Africa, and Brazil, is about 80%, while it is about 60% in created nations, for example, U.S. furthermore, U.K.

Among the numerous courses of prescription organization, patients lean toward intranasal course over different kinds, for example, buccal, rectal, and intramuscular course. Parenteral drugs have ended up being the ideal choice for outpatient treatment. In any case, in a few nations, for example, Netherlands, guardians are not met all requirements for administrating parenteral meds.


The global acute repetitive seizures market is segmented into product, and region. On the basis of product the global acute repetitive seizures marketis segmented into USL-261, Neurelis-1, AZ-002, Diastat Rectal Gel, and Others. On the basis of region the global Acute Repetitive Seizures market is segmented into Latin America, Europe, Asia Pacific, North America, and Middle East & Africa.

U.S. held a capture market share of 17.3% in 2018 in the global market. As per the data published by CDC, about 4.3 million adults and approximately 750,000 children in U.S. had epilepsy in 2014. Similarly, the whole direct and indirect cost of epilepsy in this region is projected to be about USD 15.5 billion yearly. Therefore, occurrence of a large target populace base for epilepsy drug in this region will drive the acute repetitive seizures market development.

Germany is anticipated to observer robust development over the forecast time frame due to technological progressions in clinical, scientific, and medical fields. Growing demand for antiepileptic drugs owing to increasing disease occurrence in the region raises the market development. Government initiatives, in an attempt to increase the quality of life and consciousness concerning the disease, paired with promotion of better healthcare facilities are the main boosting acute repetitive seizures market development in this region.

The Asia Pacific market is also expected to observer speedy growth on account of growing healthcare spending in emerging nations, for instance, China and India. A huge gap was witnessed in the treatment for acute repetitive seizures in the respective region. Henceforth, the need for the antiseizure drugs in these emerging nations inspires a shift in market potential from the already saturated European and North American regions to such nations.

The key players catering to the global Acute Repetitive Seizures market are Alexza Pharmaceuticals, Inc, .Neurelis, Inc.,and UCB S.A. The global players are continuously investing in R&D and innovating new product portfolio to attract more and more business opportunity from the emerging nation such as India and China.Also, Increasing R&D investments coupled with technological advancements to commercialise highly efficient products are anticipated to offer lucrative opportunities for industry participants.

Neurelis, Inc. andUCB S.A. are expected to captures the major share of the global acute repetitive seizures market owing to the commercialization of VALTOCOandUSL-261. As both the drugs (USL-261 and VALTOCO) are granted orphan drug designation, the values and price will be usually high. Also, according the studies, the preferred route of administration is nasal, which in turn will result into advanced acceptance of these two drugs.


The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report - 

Would like to place an order or any question, please feel free to contact at | +1 407 915 4157